Metabolon has made a busy start to 2014, with media reports of a planned IPO following news of its partnership with J. Craig Venter's Human Longevity. Now, GlaxoSmithKline has signed up to use Metabolon's bioinformatics and visualization tools as part of a deal to source metabolomic profiling services.
The GlaxoSmithKline executive charged with masterminding a Chinese bribery network didn't think he'd face those official accusations, Reuters reports. And no wonder: They're the most serious allegations ever leveled against a foreigner for corporate corruption in the country.
China is coming down hard on GlaxoSmithKline's local operation. After a months-long bribery probe, Chinese police have slapped Glaxo's former country chief--Mark Reilly, a Brit--and two other top Chinese executives with several counts of bribery.
China is coming down hard on GlaxoSmithKline's local operation. After a months-long bribery probe, Chinese police have charged Glaxo's former country chief and two other top execs with several counts of bribery. All could face life in prison.
What lies ahead for GlaxoSmithKline in China? The company has been waiting to find out since last summer, when investigators there charged it in a massive bribery scheme. But Glaxo may finally get some answers Wednesday, when Chinese police will brief the media about the drugmaker.
GlaxoSmithKline's last-minute gambit to switch the primary endpoint in its remaining Phase III study of the heart drug darapladib failed to pay off. The pharma giant says that its top cardio prospect flunked the second big trial just as it had the first, leaving the pharma giant staring at a likely writeoff of a one-time megablockbuster hopeful.
In light of news that polio has once again emerged as a public health emergency, vaccinemakers GlaxoSmithKline and Sanofi are reportedly on watch.
Over the past few years, the bottom-line number on R&D spending among the big 10 pharma companies--about $70 billion--has remained about the same. But behind the steady collective figure lies...
Adding to its string of respiratory victories, GlaxoSmithKline won an FDA nod for Incruse Ellipta, a once-daily COPD inhaler.
Expecting to improve its odds of success for the experimental heart drug darapladib, a top drug prospect that failed its first late-stage test, investigators at GlaxoSmithKline have changed up the primary endpoint in the remaining Phase III study that reads out later this quarter.